Want to track the performance of this manager?
Click the button below to sign up to receive monthly performance updates by email.Track Manager
Want more information on investing with this manager?
If you are interested in investing in one of Todd Hagopian's funds. Click the link below to get started.Invest Today
|(HIBEV) Hagopian Institute BioMed Extreme Value||View Fund Track Fund|
|INCEPTION (03/05/2011)||AVG. ANNUAL RETURN||S&P RETURN||ACHIEVEMENTS|
|Show Fund Strategy|
The mental health biotech sub-sector includes companies developing drugs for ADHD, depression, bipolar disorder, schizophrenia, migraines, alzheimer's, and other central nervous system conditions. Due Read More...
JUN 21, 2017 | Forbes Article
Todd Hagopian's Biotech fund has gained 18% so far this year and his Cannabis biotech picks have been big winners. But Todd is not ready to sell as he thinks the run-up is still in its early stages. Read More...
JUN 15, 2017 | Forbes Article
Todd Hagopian recently identified five sub-sectors of Biotech poised for the best potential returns under President Trump. Today Todd gives us a deep dive into NASH (Nonalcoholic Steatohepatitis), the Read More...
FEB 24, 2017 | Forbes Article
After researching the different sub-sectors within the broader sector, I have found 5 segments within Biotech that I believe will not be harmed by the Drug Pricing risk, but will be helped Read More...
FEB 08, 2017 | Forbes Article
Many biotech stocks took a beating as price gouging from the likes of Valeant (Nitropress), Mylan (epi-pens), and Turing (Daraprim) became a political issue during last year’s presidential campaign. Read More...
JAN 10, 2017 | Forbes Article
You do not have permission to view this fund. Please select the "Overview" tab, or select a fund tab above.